Aclaris Therapeutics, Inc. (ACRS)

NMS – Цена в реальном времени. Валюта: USD

4.88

-0.07 (-1.41%)

При закрытии: May 12, 2026, 4:00 PM EDT

4.88

0.00 (0.00%)

До открытия: May 13, 2026, 8:13 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Aclaris Therapeutics, Inc. (ACRS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Видео

No Data

Пресс-релизы

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Search stocks

Aclaris Therapeutics, Inc. (ACRS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Видео

No Data

Пресс-релизы

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026